Mesoblast/Teva May Have Shorter Path To Market In Chronic Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Now studying stem-cell candidate MPC-150-IM in two 600-patient Phase III trials in advanced heart failure, the partners could complete the Phase III program more quickly and less expensively.